Biolife Solutions Inc [BLFS] stock is trading at $22.75, up 5.03%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BLFS shares have gain 6.46% over the last week, with a monthly amount glided 9.96%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biolife Solutions Inc [NASDAQ: BLFS] stock has seen the most recent analyst activity on September 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $29. Previously, Jefferies started tracking the stock with Buy rating on April 04, 2024, and set its price target to $22. On July 11, 2023, Craig Hallum initiated with a Buy rating and assigned a price target of $29 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $28 on April 25, 2022. B. Riley Securities initiated its recommendation with a Buy and recommended $61 as its price target on October 19, 2021. In a note dated May 14, 2021, The Benchmark Company downgraded an Hold rating on this stock.
Biolife Solutions Inc [BLFS] stock has fluctuated between $18.70 and $29.55 over the past year. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. Biolife Solutions Inc [NASDAQ: BLFS] shares were valued at $22.75 at the most recent close of the market. An investor can expect a potential return of 31.87% based on the average BLFS price forecast.
Analyzing the BLFS fundamentals
Biolife Solutions Inc [NASDAQ:BLFS] reported sales of 105.55M for the trailing twelve months, which represents a drop of -24.54%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.1%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.03 and Total Capital is -0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.91 points at the first support level, and at 21.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.17, and for the 2nd resistance point, it is at 23.60.
Ratios To Look Out For
For context, Biolife Solutions Inc’s Current Ratio is 4.73. In addition, the Quick Ratio stands at 3.74 and the Cash Ratio stands at 2.41. Considering the valuation of this stock, the price to sales ratio is 10.25, the price to book ratio is 3.07.
Transactions by insiders
Recent insider trading involved Aebersold Sarah, Chief Human Resources Officer, that happened on Jun 16 ’25 when 711.0 shares were sold. Officer, SARAH AEBERSOLD completed a deal on Jun 16 ’25 to buy 711.0 shares. Meanwhile, 10% Owner Casdin Partners Master Fund, L sold 1.0 million shares on Jun 10 ’25.
